Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Hidradenitis Suppurativa - Overview Hidradenitis Suppurativa - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Hidradenitis Suppurativa - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Hidradenitis Suppurativa - Companies Involved in Therapeutics Development AbbVie Inc Celgene Corp Coherus BioSciences Inc Fresenius SE & Co KGaA Immunwork Inc InflaRx NV Innovation Pharmaceuticals Inc Novartis AG UCB SA XBiotech Inc Hidradenitis Suppurativa - Drug Profiles adalimumab - Drug Profile Product Description Mechanism Of Action R&D Progress adalimumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress adalimumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress adalimumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress adalimumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress apremilast - Drug Profile Product Description Mechanism Of Action R&D Progress bimekizumab - Drug Profile Product Description Mechanism Of Action R&D Progress brilacidin tetrahydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress CJM-112 - Drug Profile Product Description Mechanism Of Action R&D Progress IFX-1 - Drug Profile Product Description Mechanism Of Action R&D Progress TE-2232 - Drug Profile Product Description Mechanism Of Action R&D Progress Xilonix - Drug Profile Product Description Mechanism Of Action R&D Progress Hidradenitis Suppurativa - Dormant Projects Hidradenitis Suppurativa - Discontinued Products Hidradenitis Suppurativa - Product Development Milestones Featured News & Press Releases Jan 19, 2018: XBiotech Announces Presentation of Phase 2 Open Label Extension Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa Jan 09, 2018: InflaRx Receives IND Acceptance To Proceed With A Phase IIb Trial With Lead Candidate IFX-1 In Hidradenitis Suppurativa Dec 04, 2017: XBiotech Announces Publication of Phase II Data From Hidradenitis Suppurativa Phase II Study in The Journal of Investigative Dermatology Oct 31, 2017: Innovation Pharma Provides Update on Brilacidin Oct 03, 2017: XBiotech Announces Addition of Renowned Dermatologist Dr. William Levis to its Scientific Advisory Board Sep 07, 2017: InflaRx Reports Topline Phase IIa Clinical Results of IFX-1 for the Treatment of Hidradenitis Suppurativa Sep 07, 2017: XBiotech Announces Presentation of Phase 2 Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa Jun 12, 2017: AbbVie's Humira accepted for use in NHS Scotland Feb 22, 2017: XBiotech Completes Dosing of Subjects in PK Study Being Conducted in Connection with European Marketing Application Feb 16, 2017: XBiotech Meets Primary Endpoin

List of Tables Number of Products under Development for Hidradenitis Suppurativa, H1 2018 Number of Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 Number of Products by Stage and Target, H1 2018 Number of Products by Stage and Mechanism of Action, H1 2018 Number of Products by Stage and Route of Administration, H1 2018 Number of Products by Stage and Molecule Type, H1 2018 Hidradenitis Suppurativa - Pipeline by AbbVie Inc, H1 2018 Hidradenitis Suppurativa - Pipeline by Celgene Corp, H1 2018 Hidradenitis Suppurativa - Pipeline by Coherus BioSciences Inc, H1 2018 Hidradenitis Suppurativa - Pipeline by Fresenius SE & Co KGaA, H1 2018 Hidradenitis Suppurativa - Pipeline by Immunwork Inc, H1 2018 Hidradenitis Suppurativa - Pipeline by InflaRx NV, H1 2018 Hidradenitis Suppurativa - Pipeline by Innovation Pharmaceuticals Inc, H1 2018 Hidradenitis Suppurativa - Pipeline by Novartis AG, H1 2018 Hidradenitis Suppurativa - Pipeline by UCB SA, H1 2018 Hidradenitis Suppurativa - Pipeline by XBiotech Inc, H1 2018 Hidradenitis Suppurativa - Dormant Projects, H1 2018 Hidradenitis Suppurativa - Discontinued Products, H1 2018 List of Figures Number of Products under Development for Hidradenitis Suppurativa, H1 2018 Number of Products under Development by Companies, H1 2018 Number of Products by Targets, H1 2018 Number of Products by Stage and Targets, H1 2018 Number of Products by Mechanism of Actions, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Routes of Administration, H1 2018 Number of Products by Stage and Routes of Administration, H1 2018 Number of Products by Molecule Types, H1 2018 Number of Products by Stage and Molecule Types, H1 2018

AbbVie Inc Celgene Corp Coherus BioSciences Inc Fresenius SE & Co KGaA Immunwork Inc InflaRx NV Innovation Pharmaceuticals Inc Novartis AG UCB SA XBiotech Inc